Connecting to SEC EDGAR… PricingSign in
← All filings
Quoin Pharmaceuticals Ltd.QNRX · Nov 6, 5:18 PM ET

Quoin reports positive Netherton Syndrome interim data and up to $50.0 million private placement

Quoin Pharmaceuticals reported positive interim Phase 2/3 results for QRX003 in Netherton Syndrome, a financing of up to $50.0 million, and a net loss of about $4.9 million for the third quarter ended September 30, 2026.

AI-generated summary, checked against the filing. Can contain errors: read the original filing ↗. Not investment advice.